

MOLECULAR ANALYSIS OF SUSPECTED INDONESIAN NOONAN SYNDROME

*ANALISIS MOLEKULAR PADA PASIEN INDONESIA DENGAN SUSPEK SINDROM
NOONAN*



THESIS

**Submitted to fulfil the assignment and fit-out requisite in passing
Post Graduate Program
Master of Biomedical Science**

Iffa Mutmainah, MD

22010112420048

**FACULTY OF MEDICINE
DIPONEGORO UNIVERSITY SEMARANG
2015**

THESIS

MOLECULAR ANALYSIS OF SUSPECTED INDONESIAN NOONAN SYNDROME

Arranged by
Iffa Mutmainah, MD
22010112420048

Has been defended in front of the defense committee on July 29, 2015

And has been approved by:

The Netherlands,
Principal Supervisor,



Helger Yntema, PhD

Supervisor,




Willy Nillesen

Indonesia,
Principal Supervisor,



Prof. Sultana MH Faradz, MD, PhD
NIP: 1952 0202 1979 012 001

Supervisor,



DR. Tri Indah Winarni, MD,MSi.Med
NIP: 1966 0510 1997 02 2001

Approved by,
Head of Master Degree Program in Biomedical Science
Faculty of Medicine Diponegoro University



Dr. Achmad Zulfa Juniarto, M.Si.Med, Sp.And, Ph.D
NIP: 19700608 1997021 001

DECLARATION

I hereby declare that this thesis is my own work and has not been submitted in any form for another degree or diploma at any university or other institution of tertiary education, there are no elements belonging Plagiarism forth in Decree No. 17 of 2010. Information derived from the published or unpublished work of others has been acknowledged in the text and a list of reference is given.

Semarang, May 2015

Iffa Mutmainah

PERNYATAAN

Saya yang bertanda tangan di bawah ini menyatakan bahwa tesis ini adalah hasil pekerjaan saya sendiri dan di dalamnya tidak terdapat karya yang pernah diajukan untuk memperoleh gelar kesarjanaan di suatu perguruan tinggi atau lembaga pendidikan lainnya, serta tidak terdapat unsur-unsur yang tergolong Plagiarism sebagaimana yang dimaksud dalam Permendiknas No. 17 Tahun 2010. Pengetahuan yang diperoleh dari hasil penerbitan maupun yang belum atau tidak diterbitkan, sumbernya dijelaskan di dalam tulisan dan daftar pustaka.

Semarang, Mei 2015

Iffa Mutmainah

CURRICULUM VITAE

Name : Iffa Mutmainah
Sex : Female
Place & Date of birth : Bogor, February 3rd, 1988
Latest Degree : Medical Doctor
Address : Jl KH Soleh Iskandar. Gang Saiyan Idi No.5 Rt 002/ Rw 004
Parakan Jaya, Kemang--Bogor PO.BOX 16310
Phone : +62856 804 2165
E-mail : iffamutmainah@gmail.com

Educational Background

2006-2010 : Diponegoro University, Medical Faculty (Bachelor degree)
2010-2012 : Diponegoro University, Medical Faculty (Medical Doctor)
2013-2015 : Master in Biomedical Science Majoring in Genetic Counseling, join program with Radboud University Medical Centre Nijmegen, The Netherlands, with one year attachment.

Participations in Trainings and Courses

2012 : One day symposium “Actual and Applicable Management of Emergency Cases in Daily Practice”, Solo
2012 : World Pneumonia Day Seminar, Semarang
2013 : 11th Medical Genetic Course: From Basic to Clinic, Semarang
2013 : Cardiogenetics and Its Clinical Management, Semarang
2013 : Workshop on Writing International Research Grants and Publication, Semarang
2013 : Molecular Biology: A Recent Update, Semarang
2013 : Gene Therapy Seminar, Semarang
2013 : 3rd International Seminar on Autism and Fragile-X Syndrome, Semarang
2014 : Dysmorphology club, Leiden, The Netherlands

- 2014 : The Genome: more than just 4 letters, Arnhem, The Netherlands
2014 : Forty hours Breastfeeding Counseling using WHO's module, Jakarta
2015 : Hands-on workshop on cytogenetic and molecular genetics. Semarang

Scientific Paper

- 2010 : The difference of carcinoembryonic antigen (CEA) levels before and after therapy in patients with colorectal carcinoma. Undergraduate thesis. Medical Faculty of Diponegoro University, Semarang.

Scholarship

- 2013 : Excellent Scholarship Program of The Bureau of Planning and International Cooperation, Ministry of National Education, Government of Indonesia.

TOEFL score

- 2010 : 527

ACKNOWLEDGEMENT

It is a pleasure to express my gratitude to all of those who have contributed their skills, gave me the opportunity, and support during the entire of this master program.

My utmost gratitude to my supervisor, Prof. Sultana MH Faradz, MD, PhD for her guidance, support, and endless encouragement in finishing this thesis. My immeasurable thank to Helger Yntema, PhD for her time to teach me and her concern in my research, particularly in my manuscript, despite her extremely tight schedule.

I gratefully thank to Nicole de Leeuw, PhD for all the opportunities that have been given to me during my research in her group. I would like to express my deep gratitude to Willy Nillesen, for introducing me with all the staff in Department of Human Genetics Radboud UMC, organizing my research, and knowledge sharing. I would also like to express my sincere gratitude to DR. Tri Indah Winarni MD, MSi.Med for her patience and her guidance not only in writing the thesis but also during my master program.

I am most grateful to Prof. Ben Hamel, MD, PhD and Ineke van der Burgt for confirming the clinical features of the patients and discussing about clinical genetic particularly in Noonan syndrome. Thank you to Farmaditya EP Mundhofir MD, PhD for his support and his guidance in writing the manuscript.

I wish to thank to Martina Ruiterkamp-Versteeg for her kind help on the lab works and data interpretations. Thank you to Lan Bokseveld-Zhang, Jeroen Hooijer, Simone van den Heuvel, and Kornelia Neveling for their help on understanding the Ion torrent technique, to Nico Leijsten, Trudi Machielsen, Ronald van Beek, Martijn Bannings for their endless guidance on array analysis, to Sabine Kempers van Gessel and Liesbeth van Rossum for teaching me in the

Flouresence in situ Hybridization analysis. Thank to all the staff in Department of Human Genetics Radboud UMC, particularly M & M group analysis, for their hospitality, kind assistance, the knowledge and the friendship that they have shared over time.

I would also like to acknowledge the laboratory assistance of Centre for Biomedical Research (CEBIOR) staff; Rita Indriati, Dwi Kustiyani, Lusi Suwarsi, Wiwik Lestari, Evi Nurwulan, and Intus Apriasa during my master program. Also my sincere thank to all the patients and their families. This research would not be possible without their cooperation.

This work is supported by Excellent Scholarship Program of The Bureau of Planning and International Cooperation, Ministry of National Education and Culture, Republic of Indonesia. Thank to the staff of Excellent Scholarship Program, particularly DR. Abe Susanto, the staff of Biomedical Science Post Graduate Program; Dina Ardina, S.Sos, and Rina Bergsma, from the staff of The Embassy of The Republic of Indonesia in The Netherlands. I also would like to thank to Rens Jongerius form International office of Radboud UMC and Ineke Zalmink for their kind assistance in organizing my stay in The Netherlands.

I wish to thank Batch 7 students, Widya Eka Nugraha, Catharina E. Wulandari, Cinta C. Rudianto, Mitayani, Nura E. Vikawati, and Rendy R. Pohan, for their friendship that they have shared over time and their support to finish this thesis.

My utmost gratitude to my parents, Eem Teminawati and Tb. Soenmandjaja Rukmandis, and my in-law; Dyah Adiati Warsitosiwi and Eko Bambang Setyawan, to my husband Widya Eka Nugraha, to my brothers and sisters; Lulu Mardiah, Ahmad Abdullah, Lina Mustaqimah, Isma Muhsonah, Adam Abdurrahman, Adilfalah Abdurrahim, and Ayyub Abdussalam for their everlasting love and support.

CONTENTS

TITLE	i
APPROVAL SHEET	ii
DECLARATION.....	iii
PERNYATAAN.....	iv
CURRICULUM VITAE.....	v
ACKNOWLEDGEMENT.....	vii
CONTENTS.....	ix
ABBREVIATION	xiii
LIST OF TABLE	xvii
LIST OF FIGURES	xviii
LIST OF APPENDICES	xix
GLOSSARY.....	xx
ABSTRACT.....	xxi
ABSTRAK	xxii
CHAPTER 1 INTRODUCTION.....	1
1.1 Background	1
1.2 Research Questions	2
1.3 Research Objectives	3
1.3.1 General Research Objective.....	3
1.3.2 Specific Research Objectives.....	3
1.4 Research Benefits.....	3
1.5 Research Originality.....	3

CHAPTER 2 LITERATURE REVIEW	5
2.1 Noonan syndrome (NS) and Its Clinical Presentation	5
2.1.1 Dysmorphic Facial Features.....	5
2.1.2 Congenital Heart Defects	5
2.1.3 Short Stature.....	7
2.1.4 Other Features of Noonan syndrome	8
2.1.4.1 Skeletal	8
2.1.4.2 Reproductive and Genitourinary	8
2.1.4.3 Lymphatic System	9
2.1.4.4 Haematology	9
2.2 Pattern of inheritance	9
2.3 Diagnostic Criteria of Noonan syndrome	9
2.4 RAS-MAPK Signalling Transduction Pathway.....	9
2.5 Genetic Cause of Noonan syndrome.....	11
2.5.1 <i>PTPN11</i> gene	12
2.5.2 <i>KRAS</i> gene.....	13
2.5.3 <i>SOS1</i> gene	14
2.5.4 <i>RAF1</i> gene.....	15
2.6 Differential Diagnosis	16
2.7 Genotype-phenotype correlation.....	16
2.8 Molecular genetic analysis.....	17
2.8.1 Ion Semiconductor Sequencing (ISS).....	17
2.8.2 Interpretation of Genetic variants	20

2.8.3	The Usefulness of Noonan syndrome Genetic Testing.....	20
2.9	Management of Noonan syndrome	22
2.9.1	Feeding assessment	22
2.9.2	Cardiac evaluation.....	23
2.9.3	Growth monitoring.....	23
2.9.4	Genetic counselling.....	24
2.10	Theoretical Framework	26
2.11	Conceptual Framework	26
CHAPTER 3 RESEARCH METHODS		27
3.1	Research aspect	27
3.1.1	Research Field.....	27
3.1.2	Research Location.....	27
3.1.3	Research Period.....	27
3.1.4	Research Design.....	27
3.2	Material	27
3.2.1	Population	27
3.2.2	Sample.....	28
3.2.3	Inclusion Criteria.....	28
3.3	Clinical Examination.....	28
3.4	Laboratory Method.....	28
3.4.1	DNA Extraction	28
3.4.2	Primer Design	29
3.4.3	Automated Generation PCR Amplicon.....	29

3.4.4	Automated Ion Semiconductor Sequencing.....	29
3.4.4.1	Automated Library Preparation	30
3.4.4.2	Emulsion PCR and Enrichment for Single Gene Amplicon.....	32
3.4.4.3	Sequencing and Imaging	32
3.4.4.4	Data Analysis.....	32
3.5	Research Variables.....	33
3.6	Operational Definition	33
3.7	Data Analysis	33
3.8	Research Flow.....	34
3.9	Research Ethic.....	34
CHAPTER 4 RESULTS.....		35
4.1	General Description	35
4.2	Sequencing of Single Genes (<i>PTPN11</i> , <i>SOS1</i> , <i>KRAS</i> , <i>RAF1</i>)	38
4.3	Sequencing of Multi-gene Panels.....	40
CHAPTER 5 DISCUSSION.....		43
5.1	Clinical Findings	43
5.2	Ion Semiconductor Sequencing (ISS).....	43
CHAPTER 6 CONCLUSION AND FUTURE DIRECTIONS		45
CHAPTER 7 SUMMARY.....		46
REFERENCES.....		49
APPENDIX.....		56

ABBREVIATIONS

A2ML1	Alpha-2-Macroglobulin-Like 1
ACGS	Association of Clinical Genetic Science
ARHGEF	Rho Guanine Nucleotide Exchange Factor
ASD	Atrial Septal Defect
CBL	Casitas B-lineage Lymphoma
CDC	Centers for Disease Control and Prevention
CDC25-H	Cell Division Cycle 25-Homology
CEBIOR	Center for Biomedical Research
CFCs	Cardio Facio Cutaneous syndrome
CR	Conserved Region
DH	Dbl Homology
DNA	Deoxyribo Nucleic Acid
ECG	Electrocardiography
EEG	Electroencephalography
ENT	Ear Nose Throat
ERK	Extracellular signal Regulated Kinase
FISH	Fluorescent in situ Hybridization
FSH	Follicle Stimulating Hormone
GDP	Guanosine diphosphate
GH	Growth Hormone
GHT	Growth Hormone Therapy
Grb2	Growth factor receptor bound-protein 2

GTP	Guanosine triphosphate
HCM	Hypertrophic Cardio Myopathy
HD	Histone Domain
HL	Helicar Linker
ID	Intellectual Disability
IGF-1	Insulin-like Growth Factor-1
ISPs	Ion Sphere Particles
ISS	Ion Semiconductor Sequencing
LH	Luteinising Hormone
MAPK	Mitogen Activated Protein Kinase
MAP2K1	Mitogen-Activated Protein Kinase Kinase 1
MAP2K2	Mitogen-Activated Protein Kinase Kinase 2
MEK	MAPK/ERK Kinase
MEK1	MAPK/ERK Kinase 1
MEK2	MAPK/ERK Kinase 2
NCHS	North Country Health Services
NS	Noonan syndrome
OFC	Occipito-Frontal Circumference
PCR	Polymerase Chain Reaction
PGM	Personal Genome Machine
PH	Pleckstrin Homology
PR	Proline-rich Region
PTP	Protein Tyrosine Phosphatase

PTPN11	Protein Tyrosine Phosphatase Non-receptor type 11 gene
PVS	Pulmonary Valve Stenosis
RAF	Rapidly Accelerated Fibrosarcoma
ARAF	A-Raf proto-oncogene, serine/threonine kinase
BRAF	B-Raf proto-oncogene, serine/threonine kinase
RAF1	Raf-1 proto-oncogene, serine/threonine kinase
RAS	Rat Sarcoma viral oncogene
HRAS	Harvey-Rat Sarcoma viral oncogene
KRAS	Kirsten-Rat Sarcoma viral oncogene
NRAS	Neuroblastoma-Rat Sarcoma viral oncogene
RefSeq	Reference Sequence
REM	RAS Exchanger Motif
RIT1	RAS like without CAAX 1
RRAS	Related Rat Sarcoma viral oncogene
RTK	Receptor Tyrosine Kinase
SH2	Src-Homology 2 domain
SHOC2	Soc-2 suppressor of clear homolog (C. elegans)
SHP-2	Protein Tyrosine Phosphatase Non-receptor type 11
SIFT	Sorting Intolerant From Tolerant
SNP	Single Nucleotide Polymorphism
SOS1	Son of Sevenless homolog 1 (Drosophila)
SPRED1/2	Sprouty-related, EVH1 Domain containing 1
TS	Turner syndrome

UCSC	University of California Santa Cruz
UV	Unclassified Variant
VKGL	Vereniging Klinisch Genetische Laboratoriumdiagnostiek
VUS	Variants of Uncertain Significance
WDR59	WD Repeat domain 59
WHO	World Health Organization

LIST OF TABLES

Table 1	List of previous associated studies	4
Table 2	Facial features of NS by age	6
Table 3	Cardiac conditions of NS	7
Table 4	NS scoring system.....	10
Table 5	Genes related to NS.....	11
Table 6	The differences between NS and TS	16
Table 7	Genotype and phenotype correlation in NS	17
Table 8	In silico prediction programs for analysis of missense substitutions ..	21
Table 9	5 classes system.....	22
Table 10	PCR program for generating the amplicon	29
Table 11	Covaris E210 protocol.....	30
Table 12	Ligation program.....	31
Table 13	PCR program for generating the final amplicon	31
Table 14	Clinical finding of Turner negative patients with normal karyotype ..	36
Table 15	Genetic variants of four most common NS genes	39
Table 16	GC content in low coverage exons of four most common NS genes..	39
Table 17	Genetic variants of genes involved in NS	40
Table 18	GC content in low coverage exons of genes involved in NS	41
Table 19	False positives found by sequencing of Multi-gene panels.....	41
Table 20	All variants found by sequencing analysis	42
Table 21	Phenotype comparisons of patient 2, 4, and 7 to NS scoring system..	44

LIST OF FIGURES

Figure 1	Schematic diagram of RAS-MAPK pathway.....	12
Figure 2	Structure of PTPN11 gene and SHP-2 domain	13
Figure 3	The four isoforms of RAS genes	14
Figure 4	SOS1 protein domain and relationship.....	14
Figure 5	The structure of RAF1 protein	15
Figure 6	DNA replication	18
Figure 7	Ion torrent workflow	18
Figure 8	ISS library preparation steps	19
Figure 9	Ion semiconductor chip	20
Figure 10	Resume of Noonan syndrome management.....	25
Figure 11	The posterior view of patients who had NS face	38
Figure 11	Sequencing result of the trio.....	38

LIST OF APPENDICES

Appendix 1	List of primers	56
Appendix 2	Ethical clearance	59
Appendix 3	Article.....	60

GLOSSARY

Gene	A basic physical and functional unit of heredity.
Ion semiconductor	A next generation sequencing technique which measure the PH changes induced by hydrogen release during DNA replication to determine the nucleotide order.
Mutation	A pathogenic alteration in DNA sequence with the prevalence less than 1% of general population. Germ line mutation occurs in the ovum or sperm and can be inherited to the offspring.
Noonan syndrome	An autosomal dominant disorder characterized by distinctive facial features, congenital heart defect, and short stature.
PCR	Polymerase Chain Reaction. A laboratory technique used in order to amplify the DNA sequence through the cycle of denaturation, annealing, and elongation.
Sequencing	A technique used to identify the nucleotide order within the DNA molecule.
SNP	Single Nucleotide Polymorphism. A normal genetic variation among more than 1% of general population.
Trio	A group consists of patient and the parents.
Turner syndrome	A chromosomal disorder in female, due to absence of all or part of X chromosome in female.

ABSTRACT

Background: Noonan syndrome (NS) is a genetic disorder characterized by dysmorphic facial features, congenital heart defects, and short stature. NS is previously known as pseudo Turner syndrome (TS) due to their phenotypic similarity. However, unlike TS, NS is non-chromosomal disorder and present in both males and females. Several genes involved in RAS-MAPK pathway found to be mutated in NS and sequencing was performed in order to find the mutation in those genes.

Methods: Eight Turner phenotype patients with normal karyotype were included in this study. Clinical appearances were then compared to NS scoring system. DNA was sequenced by automated ion semiconductor sequencing for the four most common NS genes; *PTPN11*, *SOS1*, *KRAS*, and *RAF1*. The data was subsequently analyzed using Sequence pilot software. In silico prediction programs were used to predict the pathogenic effect of the genetic variants and classified according to existing guideline.

Result: Three out of eight patients consider had NS face. One patient, who showed cardinal symptoms of NS, carried mutation of *PTPN11* gene: an A→C transition at position 317 in exon 3 indicating an Asp106Ala substitution. Other variants found in *SOS1*, *KRAS*, and *RAF1* were classified either polymorphism or unlikely to be pathogenic. The remaining five patients considered as not having NS face.

Conclusion: The molecular analysis in this study revealed NS in one out of eight Turner phenotype patients with normal karyotype. No pathogenic variant found in other patients may indicate that there is either a novel unidentified gene for NS or the patients have another disorder and not NS.

Keyword: Noonan syndrome, *PTPN11*, *SOS1*, *KRAS*, *RAF1*, ion semiconductor sequencing

ABSTRAK

Pendahuluan: Sindrom Noonan (NS) merupakan kelainan genetik yang ditandai dengan dismorfik pada wajah, kelainan jantung bawaan, dan perawakan pendek. Pada awalnya, NS disebut sebagai pseudo sindrom Turner (TS) dikarenakan kemiripan fenotipenya. Namun demikian, berbeda dengan TS, NS tidak termasuk kedalam kelainan kromosom dan dapat terjadi pada laki-laki dan perempuan. Mutasi pada gen-gen yang berperan dalam jalur RAS-MAPK menyebabkan terjadinya NS. Sekuensing dilakukan untuk menemukan mutasi pada gen tersebut.

Metode: Delapan pasien yang memiliki fenotipe turner dan kariotipe normal diikuti dalam penelitian ini. Tampilan klinis pasien dibandingkan dengan sistem skoring NS. DNA di sekuens dengan menggunakan *automated ion semiconductor sequencing* untuk empat gen utama penyebab NS yaitu *PTPN11*, *SOS1*, *KRAS*, dan *RAF1*. Data selanjutnya dianalisis menggunakan *Sequence pilot software*. Prediksi efek patogenik dari varian yang ditemukan adalah dengan menggunakan program komputer dan diklasifikasi berdasarkan pedoman yang telah ada.

Hasil: Tiga dari delapan pasien dipertimbangkan memiliki tampilan wajah NS. Satu pasien dengan tanda kardinal NS memiliki mutasi gen *PTPN11*: terjadi perubahan basa A → C di posisi ke 317 pada ekson 3 menyebabkan substitusi Asp106Ala. Varian lain yang ditemukan pada gen *SOS1*, *KRAS*, dan *RAF1* diklasifikasikan sebagai polimorfisme atau tidak patogenik. Lima pasien lainnya dipertimbangkan tidak memiliki tampilan wajah NS.

Kesimpulan: Analisis molekular dalam penelitian ini menemukan NS pada satu dari delapan pasien yang memiliki fenotipe turner dan kariotipe normal. Pada pasien lainnya, tidak ditemukan varian patogenik. Hal ini menunjukkan kemungkinan terdapat gen NS lain yang belum teridentifikasi atau pasien tersebut memiliki kelainan lainnya dan bukan NS.

Kata Kunci: Sindrom Noonan, *PTPN11*, *SOS1*, *KRAS*, *RAF1*, ion semiconductor sequencing